Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov February 1 2019 9 (2) 151-154; DOI:10.1158/2159-8290.CD-ITI9-2

In the Spotlight

  • In the Spotlight
    Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas
    Samuel J. Klempner and Daniel V.T. Catenacci
    Cancer Discov February 1 2019 9 (2) 166-168; DOI:10.1158/2159-8290.CD-18-1447

  • In the Spotlight
    Drugging RB1 Deficiency: Synthetic Lethality with Aurora Kinases
    Frederick A. Dick and Shawn Shun-Cheng Li
    Cancer Discov February 1 2019 9 (2) 169-172; DOI:10.1158/2159-8290.CD-18-1448

  • In the Spotlight
    Two Birds with One Stone: Therapeutic Targeting of IL1α Signaling Pathways in Pancreatic Ductal Adenocarcinoma and the Cancer-Associated Fibroblasts
    Jianhua Ling and Paul J. Chiao
    Cancer Discov February 1 2019 9 (2) 173-175; DOI:10.1158/2159-8290.CD-18-1460

Review

  • Review | AuthorChoice
    Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
    Ana C. Garrido-Castro, Nancy U. Lin and Kornelia Polyak
    Cancer Discov February 1 2019 9 (2) 176-198; DOI:10.1158/2159-8290.CD-18-1177

Research Briefs

  • Research Briefs | AuthorChoice
    EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
    Francisco Sanchez-Vega, Jaclyn F. Hechtman, Pau Castel, Geoffrey Y. Ku, Yaelle Tuvy, Helen Won, Christopher J. Fong, Nancy Bouvier, Gouri J. Nanjangud, Joanne Soong, Efsevia Vakiani, Mark Schattner, David P. Kelsen, Robert A. Lefkowitz, Karen Brown, Mario E. Lacouture, Marinela Capanu, Marissa Mattar, Besnik Qeriqi, Fabiola Cecchi, Yuan Tian, Todd Hembrough, Rebecca J. Nagy, Richard B. Lanman, Steven M. Larson, Neeta Pandit-Taskar, Heiko Schöder, Christine A. Iacobuzio-Donahue, David H. Ilson, Wolfgang A. Weber, Michael F. Berger, Elisa de Stanchina, Barry S. Taylor, Jason S. Lewis, David B. Solit, Jorge A. Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz and Yelena Y. Janjigian
    Cancer Discov February 1 2019 9 (2) 199-209; DOI:10.1158/2159-8290.CD-18-0598

    Coamplification of EGFR and ERBB2 is associated with afatinib response in patients with trastuzumab-refractory esophagogastric cancer, whereas selection for MET amplification or loss of EGFR amplification is associated with resistance.

  • Research Briefs | AuthorChoice
    BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
    Kevin K. Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray-Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O'Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James X. Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish and Elizabeth M. Swisher
    Cancer Discov February 1 2019 9 (2) 210-219; DOI:10.1158/2159-8290.CD-18-0715

    Analysis of cfDNA from 112 patients with high-grade ovarian carcinoma showed that BRCA reversion mutations may be associated with reduced clinical benefit from the PARP inhibitor rucaparib.

  • Research Briefs | AuthorChoice
    PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer
    Vito W. Rebecca, Michael C. Nicastri, Colin Fennelly, Cynthia I. Chude, Julie S. Barber-Rotenberg, Amruta Ronghe, Quentin McAfee, Noel P. McLaughlin, Gao Zhang, Aaron R. Goldman, Rani Ojha, Shengfu Piao, Estela Noguera-Ortega, Alessandra Martorella, Gretchen M. Alicea, Jennifer J. Lee, Lynn M. Schuchter, Xiaowei Xu, Meenhard Herlyn, Ronen Marmorstein, Phyllis A. Gimotty, David W. Speicher, Jeffrey D. Winkler and Ravi K. Amaravadi
    Cancer Discov February 1 2019 9 (2) 220-229; DOI:10.1158/2159-8290.CD-18-0706

    Chloroquine derivatives exert their antiautophagic and antitumor effects by binding palmitoyl-protein thioesterase 1 (PPT1) and inhibiting its enzymatic activity.

Research Articles

  • Research Articles
    Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
    Matthew G. Oser, Raquel Fonseca, Abhishek A. Chakraborty, Rachel Brough, Alexander Spektor, Rebecca B. Jennings, Abdallah Flaifel, Jesse S. Novak, Aditi Gulati, Elizabeth Buss, Scott T. Younger, Samuel K. McBrayer, Glenn S. Cowley, Dennis M. Bonal, Quang-De Nguyen, Laura Brulle-Soumare, Paula Taylor, Stefano Cairo, Colm J. Ryan, Elizabeth J. Pease, Kim Maratea, Jon Travers, David E. Root, Sabina Signoretti, David Pellman, Susan Ashton, Christopher J. Lord, Simon T. Barry and William G. Kaelin Jr
    Cancer Discov February 1 2019 9 (2) 230-247; DOI:10.1158/2159-8290.CD-18-0389

    A CRISPR/Cas9 screen identifi es a synthetic lethal relationship between RB1 and AURKB loss in SCLC cells.

  • Research Articles | AuthorChoice
    Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
    Xueqian Gong, Jian Du, Stephen H. Parsons, Farhana F. Merzoug, Yue Webster, Philip W. Iversen, Li-Chun Chio, Robert D. Van Horn, Xi Lin, Wayne Blosser, Bomie Han, Shaoling Jin, Sufang Yao, Huimin Bian, Chris Ficklin, Li Fan, Avnish Kapoor, Stephen Antonysamy, Ann M. Mc Nulty, Karen Froning, Danalyn Manglicmot, Anna Pustilnik, Kenneth Weichert, Stephen R. Wasserman, Michele Dowless, Carlos Marugán, Carmen Baquero, María José Lallena, Scott W. Eastman, Yu-Hua Hui, Matthew Z. Dieter, Thompson Doman, Shaoyou Chu, Hui-Rong Qian, Xiang S. Ye, David A. Barda, Gregory D. Plowman, Christoph Reinhard, Robert M. Campbell, James R. Henry and Sean G. Buchanan
    Cancer Discov February 1 2019 9 (2) 248-263; DOI:10.1158/2159-8290.CD-18-0469

    A screen of cell-cycle inhibitors reveals that RB1-mutant cancer cells are selectively dependent on Aurora kinase A.

  • Research Articles
    EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
    Gnana P. Krishnamoorthy, Natalie R. Davidson, Steven D. Leach, Zhen Zhao, Scott W. Lowe, Gina Lee, Iňigo Landa, James Nagarajah, Mahesh Saqcena, Kamini Singh, Hans-Guido Wendel, Snjezana Dogan, Prasanna P. Tamarapu, John Blenis, Ronald A. Ghossein, Jeffrey A. Knauf, Gunnar Rätsch and James A. Fagin
    Cancer Discov February 1 2019 9 (2) 264-281; DOI:10.1158/2159-8290.CD-18-0606

    The EIF1AX-A113spl mutation results in an alternatively spliced transcript that cooperates with RAS mutations to stabilize MYC, activate mTOR, and promote tumorigenesis.

  • Research Articles | AuthorChoice
    IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma
    Giulia Biffi, Tobiloba E. Oni, Benjamin Spielman, Yuan Hao, Ela Elyada, Youngkyu Park, Jonathan Preall and David A. Tuveson
    Cancer Discov February 1 2019 9 (2) 282-301; DOI:10.1158/2159-8290.CD-18-0710

    TGFβ antagonizes IL1-driven JAK/STAT activation, which induces an inflammatory pancreatic ductal adenocarcinoma cancer-associated fi broblast (CAF) phenotype, to promote CAF heterogeneity.

News in Brief

  • News in Brief
    People
    Cancer Discov February 1 2019 9 (2) 156-156; DOI:10.1158/2159-8290.CD-NB2018-173

  • News in Brief
    BCL2/MDM2 Inhibitor Combo Effective in AML
    Cancer Discov February 1 2019 9 (2) 156-156; DOI:10.1158/2159-8290.CD-NB2019-003

  • News in Brief
    Personalized Medicine Applied to AML
    Cancer Discov February 1 2019 9 (2) 156-157; DOI:10.1158/2159-8290.CD-NB2018-164

  • News in Brief
    BiTE Therapy Active in Multiple Myeloma
    Cancer Discov February 1 2019 9 (2) 157-158; DOI:10.1158/2159-8290.CD-NB2019-001

  • News in Brief
    Augmenting CAR T Cells with PD-1 Blockade
    Cancer Discov February 1 2019 9 (2) 158-158; DOI:10.1158/2159-8290.CD-NB2018-165

  • News in Brief
    T-DM1 Reduces HER2+ Breast Cancer Recurrence
    Cancer Discov February 1 2019 9 (2) 158-159; DOI:10.1158/2159-8290.CD-NB2018-169

  • News in Brief
    GSK to Buy Tesaro, Developer of Niraparib
    Cancer Discov February 1 2019 9 (2) 159-159; DOI:10.1158/2159-8290.CD-NB2018-168

  • News in Brief
    New Endpoints, Programs Used for Drug Approvals
    Cancer Discov February 1 2019 9 (2) 160-160; DOI:10.1158/2159-8290.CD-NB2019-010

  • News in Brief
    By the Numbers: NCI Budget Breakdown, FY 2018
    Cancer Discov February 1 2019 9 (2) 160-160; DOI:10.1158/2159-8290.CD-NB2019-002

  • News in Brief
    Noted
    Cancer Discov February 1 2019 9 (2) 160-160; DOI:10.1158/2159-8290.CD-NB2018-172

  • News in Brief
    Mixed Reviews for New AML Drugs
    Cancer Discov February 1 2019 9 (2) OF1-OF1; DOI:10.1158/2159-8290.CD-NB2018-171

  • News in Brief
    Truxima Gets High Marks from Physicians
    Cancer Discov February 1 2019 9 (2) OF2-OF2; DOI:10.1158/2159-8290.CD-NB2018-170

  • News in Brief
    Ibrutinib May Boost Efficacy of CAR T Cells
    Cancer Discov February 1 2019 9 (2) OF3-OF3; DOI:10.1158/2159-8290.CD-NB2018-167

  • News in Brief
    First-Line Ibrutinib Confirmed for CLL
    Cancer Discov February 1 2019 9 (2) OF4-OF4; DOI:10.1158/2159-8290.CD-NB2018-166

Research Watch

  • Breast Cancer

    • Research Watch
      TINAGL1 Represses Breast Cancer Tumorigenesis and Metastasis
      Cancer Discov February 1 2019 9 (2) 164-164; DOI:10.1158/2159-8290.CD-RW2019-004

    • Research Watch
      Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer
      Cancer Discov February 1 2019 9 (2) 161-161; DOI:10.1158/2159-8290.CD-RW2018-215

  • DNA Repair

    • Research Watch
      UBQLN4 Regulates DNA Repair Pathway Choice
      Cancer Discov February 1 2019 9 (2) 163-163; DOI:10.1158/2159-8290.CD-RW2019-006

  • Glioma

    • Research Watch
      Unique Molecular Landscapes Distinguish Low- and High-Grade NF1 Gliomas
      Cancer Discov February 1 2019 9 (2) 165-165; DOI:10.1158/2159-8290.CD-RW2018-217

  • Immunology

    • Research Watch
      A Catecholamine Loop Mediates Cytokine Release Syndrome
      Cancer Discov February 1 2019 9 (2) OF5-OF5; DOI:10.1158/2159-8290.CD-RW2019-002

  • Immunotherapy

    • Research Watch
      Reducing Activation Potential Enhances CAR T-cell Persistence
      Cancer Discov February 1 2019 9 (2) 164-164; DOI:10.1158/2159-8290.CD-RW2019-001

    • Research Watch
      The E3 Ligase FBXO38 Controls PD-1 Expression and Antitumor Immunity
      Cancer Discov February 1 2019 9 (2) 162-162; DOI:10.1158/2159-8290.CD-RW2018-213

  • Lymphoma

    • Research Watch
      BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression
      Cancer Discov February 1 2019 9 (2) 162-162; DOI:10.1158/2159-8290.CD-RW2018-216

  • Metabolism

    • Research Watch
      Mannose Inhibits Tumor Growth and Increases Tumor Chemosensitivity
      Cancer Discov February 1 2019 9 (2) OF6-OF6; DOI:10.1158/2159-8290.CD-RW2018-214

  • Targeted Therapy

    • Research Watch
      Non–Cell Autonomous NK Cell Effects Underlie Combination Therapy Efficacy
      Cancer Discov February 1 2019 9 (2) 165-165; DOI:10.1158/2159-8290.CD-RW2019-003

  • Transcription

    • Research Watch
      Transcription Factor Motif Density Can Confer Transcriptional Addiction
      Cancer Discov February 1 2019 9 (2) 161-161; DOI:10.1158/2159-8290.CD-RW2018-212

  • Translation

    • Research Watch
      KRAS-Driven Cancers Are Dependent on METTL13-Mediated eEF1A Methylation
      Cancer Discov February 1 2019 9 (2) 163-163; DOI:10.1158/2159-8290.CD-RW2019-005

Corrections

  • Corrections | Free Article
    Correction: Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy
    Thomas Stricker and Carlos L. Arteaga
    Cancer Discov February 1 2019 9 (2) 302-302; DOI:10.1158/2159-8290.CD-18-1514

  • Corrections | Free Article
    Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
    Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler and Carlos L. Arteaga
    Cancer Discov February 1 2019 9 (2) 303-303; DOI:10.1158/2159-8290.CD-18-1515

  • Corrections | Free Article
    Correction: Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
    Angel L. Guerrero-Zotano and Carlos L. Arteaga
    Cancer Discov February 1 2019 9 (2) 304-304; DOI:10.1158/2159-8290.CD-18-1516

Back to top
Previous
Cancer Discovery: 9 (2)
February 2019
Volume 9, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • In This Issue
  • In the Spotlight
  • Review
  • Research Briefs
  • Research Articles
  • News in Brief
  • Research Watch
    • Breast Cancer
    • DNA Repair
    • Glioma
    • Immunology
    • Immunotherapy
    • Lymphoma
    • Metabolism
    • Targeted Therapy
    • Transcription
    • Translation
  • Corrections
Advertisement
  • Most Cited
  • Most Read
Loading
  • The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  • Macrophages Regulate Response to Chemotherapy
  • EGFR Mediates RAF Inhibitor Resistance in BRAF-Mutant Colorectal Cancer
  • Core Resistance Mechanisms and Genetic Evolution of Melanoma under BRAF Inhibitor Selection
  • Novel Mutant-Selective EGFR Inhibitor Overcomes Drug Resistance
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement